Craneware plc (CRW) Fair Value & Analysis
Healthcare · GB · Market cap 531M GBX
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Share price −10.4% over the past month.
Price vs Fair Value (12 months)
12‑month range £12.92 – £25.54 · fair‑value band £9.48 – £15.79 · the £13.50 price screens above the £12.63 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Craneware plc (CRW) currently trades at £13.50, while our model-based Fair Value estimate is £12.63 — implying the stock looks roughly 6.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Craneware plc generated revenue of £211M at a net margin of 10.6%. Revenue grew 5.7% year over year. It earns a return on equity of 6.7%. The balance sheet holds a net cash position of £24.3M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Craneware plc reported revenue of £206M in FY2025 versus £75.6M in FY2021, a compound +28.4%/yr. Reported net income was £19.7M in FY2025, compounding +11.1%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $163.76 | $103.58 | -37% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $57.40 | $23.87 | -58% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.61 | $79.57 | -6% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Craneware plc (CRW) undervalued?
What is the fair value of CRW?
What is the quality score of CRW?
What is the revenue of Craneware plc (CRW)?
What is the net profit margin of CRW?
Does Craneware plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.